Literature DB >> 9855339

Interaction between tacrolimus and nefazodone in a stable renal transplant recipient.

A J Olyaei1, A M deMattos, D J Norman, W M Bennett.   

Abstract

Tacrolimus (FK-506) is an important immunosuppressive agent most often given for maintenance immunosuppression to prevent acute cellular organ rejection. A 57-year-old woman with end-stage renal disease presumed secondary to chronic glomerulonephritis underwent a living related renal allograft transplantation. She tolerated the surgery well and was discharged on postoperative day 5. She was stabilized with prednisone, azathioprine, and tacrolimus. Two years after transplantation, nefazodone 50 mg twice/day orally was prescribed due to depression. After 1 week of nefazodone therapy the patient experienced headache, confusion, and "gray areas" in her vision, without abnormal ophthalmologic findings. Her serum creatinine was elevated to 2.2 mg/dl (baseline 1.5 mg/dl), and trough tacrolimus level was markedly elevated (> 30 ng/ml). Both tacrolimus and nefazodone are metabolized by the cytochrome P450 (CYP) 3A4 system. We suspect that nefazodone inhibits metabolism of tacrolimus. Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to interfere with tacrolimus metabolism. Monitoring blood concentrations of tacrolimus is vital, and appropriate dosage adjustments are required when the two drugs are administered concurrently to avoid serious interactions such as nephrotoxicity and neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855339

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  Tacrolimus-induced encephalopathy and polyneuropathy in a renal transplant recipient.

Authors:  Geru Wu; Francis L Weng; Vasanthi Balaraman
Journal:  BMJ Case Rep       Date:  2013-12-05

Review 2.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Central and peripheral vision loss associated with nefazodone usage.

Authors:  Chi Luu; Patricia Kiely; David Crewther; Lionel Kowal; Sheila Crewther
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

Review 4.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.